Viatris Stock
Viatris Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Scott Andrew Smith
- Employees
- 30,000
- Market cap
- $21.4 B
- IPO
- 17/03/1980
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise headquartered in Canonsburg, USA. The company's business model encompasses the manufacturing and distribution of a comprehensive range of pharmaceutical products, including branded prescription medications, generics, complex generics,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Viatris stock: price history
1D
+2.4%
1W
+5.8%
1M
+9.6%
6M
+27.1%
YTD
+49.9%
1Y
+84.8%
2Y
+57.9%
5Y
+38.6%
10Y
-50.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~83% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Viatris stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
2 more assignments (Enabler/Second row) Pro-only.
Viatris Inc. is a global pharmaceutical company offering products across the segments of branded medicines, generics, biosimilars, and active pharmaceutical ingredients (APIs). Business operations span various geographic markets, including developed markets as well as China, emerging markets, and Asia-Pacific. The portfolio encompasses a broad range of therapeutics for areas such as oncology, immunology, and endocrinology. In addition to distributing medicines in various pharmaceutical forms, the company also supplies active ingredients to other manufacturers. Distribution is conducted through an extensive network of pharmacies, wholesalers, government agencies, as well as insurers and medical facilities worldwide. To promote innovation, Viatris also relies on strategic partnerships and licensing agreements.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Low
Suppliers & customers in our universe
Theravance Biopharma IncDescriptionAsk the agents about Viatris
Analyst assessment of Viatris
PRICE TARGET LOW
US$20.00
CONSENSUS
US$22.17
MEDIAN
US$21.00
PRICE TARGET HIGH
US$26.00
0
STRONG BUY
5
BUY
7
HOLD
1
SELL
0
STRONG SELL
13
TOTAL · Hold
As of: 05/10/2026
Viatris stock metrics
P/E
-51.82
P/B
1.52
EV/EBITDA
12.58
RETURN ON EQUITY
-0.8%
NET MARGIN
-3.2%
DEBT/EQUITY
0.96
DIVIDEND YIELD
2.6%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.4%
FLOAT SHARES
1,141,791,206
AVG. DAILY VOLUME (30D)
8,855,395
Insider transactions (SEC)
Enrietti Andrew
Enrietti Andrew
Enrietti Andrew
Enrietti Andrew
Campbell Paul
Attention
Price since yesterday: +2.4%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Viatris stock
What does Viatris do?
Viatris Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Scott Andrew Smith, the company employs around 30,000 people.
The IPO was on 17/03/1980; the stock trades on NASDAQ under the ticker VTRS.
What do analysts say about Viatris stock?
13 analysts rate the stock, the consensus is Hold (as of 05/10/2026).
The average price target is US$22.17, ranging from US$20.00 to US$26.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Viatris report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 83% stronger than usual.
Does Viatris pay a dividend?
Yes. The last dividend was US$0.12 per share, ex-date 21/08/2026, paid on 16/09/2026.
The dividend yield is 2.6% (as of 30/06/2026).
Which stocks are comparable to Viatris?
Comparable stocks include Zoetis, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences, Amphastar Pharmaceuticals and Aquestive Therapeutics.
How can I get Viatris stock analyzed?
Clicking "Analyze stock" lets five strategies assess Viatris against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.